Regedent AG, Zürich   Report issue

For profit Phase 4
Founded: Zurich Switzerland (2013)

Organization Overview

First Clinical Trial
2020
NCT04274244
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Regedent AG, Zürich

Active Ingredients

Drugs in Phase 4 Trials (1)

hyaluronic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alveolar Bone Loss (Phase 4)

Chronic Periodontitis (Phase 4)

Periodontitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1